Bluebird bio

Biotech & Life Sciences · Cambridge, United States · Founded 1993 · IPO 2013

Integrated product platforms encompass gene therapy, cancer immunotherapy and gene editing

Valuation $150M

Revenue $84M

Power Law Thoroughbred$100M+ revenue

Talent graph

Bluebird bio's talent

Book a demo to see the people

Employees mapped 308 incl. 2 AI specialists

Founders /100 quality score

Key operators 7 quality /100

Potential founders likely future founders

Startup mafia 8 alumni-founded startups

Talent movements in · out past 12 months

Source: Dealroom Talent Intelligence.

Investors

12 investors on Bluebird bio's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series B+ 12 investors entered at this stage

Third Rock Ventures

Sanofi Ventures

Forbion Capital Partners

California Institute for Regenerative Medicine

TVM Capital Life Science

Techno Venture Management

ARCH Venture Partners

RA Capital Management

Massachusetts Institute of Technology

Deerfield Partners

Sanofi-Genzyme BioVentures

Whitehead Institute

Bluebird bio mafia

Startups founded by Bluebird bio alumni

Former Bluebird bio employees who went on to start their own companies. Sorted by Dealroom signal score.

Umoja BiopharmaEst. 2019

Andy ScharenbergUnited States

Signal score88

Kelonia TherapeuticsEst. 2020

Kevin FriedmanUnited States

Signal score84

EmphereEst. 2025

Ankit KumarUnited States

Signal score74

Generation BioEst. 2016

MAMark D. AngelinoUnited States

Signal score62

OncorusEst. 2015

Cyrus MozayeniUnited States

Signal score62

Chameleon BiosciencesEst. 2017

Genine WInslowUnited States

Signal score56

Epigene LabsEst. 2019

Akpeli NordorFrance

Signal score51

Luna GeneticsEst. 2018

Philip ReillyUnited States

Signal score45

Book a demo to explore the full alumni network →

Global footprint

Where Bluebird bio has talent and traffic

Workforce by country

13 countries with
team presence

🇺🇸 United States93.5%

🇫🇷 France1.3%

🇿🇦 South Africa0.9%

🇮🇳 India0.9%

🇧🇷 Brazil0.5%

Top 5 of 13 shown

Web traffic by country

3.2K monthly visits
across markets

🇮🇳 India56.3%

🇺🇸 United States40.6%

Top 2 markets shown

Patent intelligence

$100M patent portfolio · 43 active families

Estimated portfolio value

$100M

66.4% of market cap · 1.7× larger than top peer TP Therapeutics ($60M)

43 active patent families

Where Bluebird bio innovates Autoimmune conditionAutoimmune diseaseCancer researchCarcinosisCell

Where Bluebird bio concentrates vs peers

Each axis is a top-10 topic across Bluebird bio and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Bluebird bio

An AI-synthesized read of the highest-engagement posts about Bluebird bio on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Bluebird bio on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles